Medline's stock soared more than 40% above its IPO price on Wednesday, its first day of trading. ...

Medline (MDLN) stock rose 40% on Wednesday to close at $40.66, as investors warmly greeted the year's biggest IPO on one of the last trading days of the year. The medical supply giant said late Tuesday that it had raised $6.26 billion in its IPO, selling a little over 216 million shares at $29 each, with the stock set to begin trading on Wednesday. Based on a total Class A share count of around 1.3 billion, the company's market cap stood north of $50 billion at the close of trading on Wednesday. Privat ...

A day that featured the biggest initial public offering in four years also saw the Nasdaq Composite close sharply lower.The tech-heavy index slid 1.8%. The S&P 500 dropped 1.1%. The Dow Jones Industrial Average fell 230 points, or 0.5%. The S&P and Dow extended their respective losing streaks to four days.Struggles for the Nasdaq were in stark contrast to Medline, which surged in its debut on the tech-heavy index under the MDLN ticker. It raised $6.26 billion in the initial public offering, which makes it t ...

Core Insights - Medline Inc. completed a $6.26 billion IPO, marking the largest global IPO of 2025 and receiving strong investor interest on its first trading day [1][3] Group 1: IPO Details - Medline's stock debuted on NASDAQ under the ticker MDLN at an opening price of $35, a nearly 21% increase from the $29 issue price, reaching over $38 during trading, with a peak increase of over 30% [3] - The IPO involved the sale of 216 million shares, with the opening valuation of Medline reaching $47 billion, approximately 40% higher than its valuation during a 2021 acquisition by private equity firms [3][6] - This IPO surpassed the previous record held by CATL's $5.26 billion listing, making it the largest IPO of the year and the largest in the U.S. since Rivian's $13.7 billion IPO in 2021 [3][6] Group 2: Market Impact - Medline's successful IPO contributed to a total IPO fundraising exceeding $46 billion for the year, boosting optimism for the 2026 IPO market, potentially setting the stage for significant listings like SpaceX [4][10] - The IPO received over 10 times the subscription demand, leading to an increase in the number of shares issued from an initial plan of 179 million to 216 million [5] Group 3: Company Background - Medline, founded in 1966, specializes in manufacturing and distributing medical supplies, serving hospitals and clinics with a product range of approximately 335,000 items [6] - The company was acquired by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman in 2021 for up to $34 billion, marking one of the largest leveraged buyouts in history [6] - Medline's CEO, Jim Boyle, aims to position the company as the "Costco of healthcare," emphasizing a strong supply chain and a loyal customer base [7] Group 4: Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million and revenue of $20.6 billion, compared to $911 million and $18.7 billion in the same period the previous year [7] - The company anticipates a total revenue of $25.5 billion for the full year of 2024 [7] Group 5: Challenges and Strategic Moves - Medline faced challenges in its IPO journey due to uncertainties from U.S. tariff policies and a government shutdown, which delayed its initial plans for a mid-2023 listing [8] - The company has made strategic investments, including a $905 million acquisition of Ecolab Inc.'s surgical solutions business and $1.6 billion in capital expenditures over the past five years to enhance its distribution network [9]

Company Overview - Medline, a key manufacturer and distributor of medical supplies, was founded in 1966 and is based in Northfield, Illinois. The company produces items such as surgical kits, gloves, and gowns used by hospitals globally [6][9] - Medline has maintained net sales growth every year since its inception, even through economic cycles and the COVID-19 pandemic [6] IPO Details - Medline shares surged over 40% during its New York debut, valuing the company at $54 billion, marking the largest US IPO since Rivian's listing in 2021 [1] - The company sold 216 million shares at an IPO price of $29 per share, raising $6.26 billion, making it the largest private-equity-backed IPO ever [2][4] - The stock opened at $35 and closed at $41 on its first day of trading [1] Financial Performance - For the nine months ending September 27, Medline reported a net income of $977 million on revenue of $20.6 billion, an increase from $911 million on $18.7 billion in the same period the previous year [11] Market Position and Strategy - Medline's dominant position in branded medical equipment has attracted investors, who appreciate its growth prospects and relative insulation from broader economic fluctuations [10] - The company operates 33 facilities, with about half of its output coming from the US or North America, allowing it to mitigate tariff impacts [7][9] - CEO Jim Boyle stated that the IPO will enable the company to reduce debt and enhance its market presence while continuing to operate as before [4][13] Industry Context - The IPO market in the US has shown resilience in 2025, with first-time share sales raising a total of $46.15 billion, the highest since 2021 [14] - The successful listing of Medline may encourage more private equity-backed firms to pursue IPOs [18]

Core Viewpoint - The IPO of Medline, the largest of the year, opened at $35 per share, reflecting strong demand despite a generally weak IPO market [1][2] Group 1: IPO Performance - Medline's shares increased by over 20% from the IPO price of $29, indicating strong market interest [2] - The company raised more than $6 billion in an upsized deal, selling more shares than initially planned [2] - The current market capitalization of Medline is approximately $20 billion higher than the acquisition price by private equity firms four years ago [3] Group 2: Company Background - Medline has been a private company for 58 years, primarily family-owned until its buyout by private equity firms in 2021 [2] - The company has a significant debt load of about $17 billion, which it plans to address using IPO proceeds [3][4] - Medline has demonstrated consistent growth, with net sales increasing annually at a compound annual growth rate (CAGR) of 18% since inception [4] Group 3: Market Implications - The successful IPO and share performance, currently up about 27%, may signal a positive outlook for future IPOs, particularly for private equity-owned companies [5] - The performance of Medline's IPO could alleviate some challenges faced in the IPO market over the past few years, potentially reducing the backlog of companies waiting to go public [5]

Core Insights - Medical supply firm Medline's stock price increased by approximately 29% on its first day of trading on the Nasdaq [1] - The company raised $6.26 billion, marking the largest initial public offering (IPO) of the year [1] Company Overview - Medline's CEO, Jim Boyle, participated in the opening bell ceremony at the Nasdaq [1]

Core Insights - Medline shares experienced a significant increase of nearly 25% during their trading debut, with the stock priced around $36 after an IPO that raised $6.26 billion, marking one of the largest IPOs in recent years [1][4][7] Company Overview - Medline sold over 216 million shares at $29 each, at the higher end of its anticipated range of $26 to $30, with plans to use the proceeds to reduce debt [2][4] - The company offers over 335,000 medical and surgical products, including protective equipment and testing kits, and has reported consistent annual sales growth since its inception [2] Financial Performance - For the first nine months of the year ending September, Medline reported a net income of $977 million on revenues of $20.65 billion, an increase from a net income of $911 million on $18.72 billion in revenue during the same period the previous year [3] Market Context - The IPO marks a recovery in the IPO market, although overall activity remains below the record levels seen in 2021; Medline's IPO is the largest since Rivian's $11.93 billion IPO in 2021 [4][7] Strategic Vision - CEO Jim Boyle expressed that the IPO is expected to enhance Medline's brand, positioning the company as the "Costco of healthcare" for its medical equipment customers, leveraging its private label products and strong supply chain [5]

Group 1 - Medline shares commenced trading under the ticker 'MDLN' on Wednesday, marking the largest IPO since 2021 [1]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...